3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
11
Neoplasms
3
HER2-positive Breast Cancer
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Endometrial Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Hemangiosarcoma
1
HR+/HER2+ Early Breast Cancer
1
Glioma
1
Interventions
Cyclophosphamide
11
fludarabine phosphate
8
Nivolumab
8
pembrolizumab
7
fludarabine
7
Mycophenolic Acid
6
Magnetic Resonance Spectroscopy
6
Filgrastim
6
Doxorubicin
6
Dacarbazine
6
Brentuximab Vedotin
6
Whole-Body Irradiation
5
Vinblastine
5
Granulocyte Colony-Stimulating Factor
5
Cyclosporine
5
Specimen Handling
4
Melphalan
4
Etoposide
4
Busulfan
4
pegfilgrastim
3
Tacrolimus
3
Radiotherapy
3
Thiotepa
2
Sirolimus
2
Radiation
2
Peripheral Blood Stem Cell Transplantation
2
Fluorodeoxyglucose F18
2
Cyclosporins
2
Clofarabine
2
Azacitidine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
pertuzumab
×
30 days
×
Clear all
No trials found.